Abstract
Anthrax caused by Bacillus anthracis is a lethal infectious disease, especially when inhaled, and the mortality rate approaches 100% without treatment. The anthrax antitoxin monoclonal antibody (MAb) 5E11 is a humanized antibody that targets the anthrax protective antigen (PA). The efficacy of 5E11 needs proper animal models. However, anthrax spores are extremely dangerous, so experiments must be conducted under Biosafety Level 3 conditions. Considering the critical effects of lethal toxin (LT) on hosts during infection, we report the establishment of a LT-challenged rabbit model, which caused 100% mortality with a dose of 2 mg PA + 1 mg LF, while a 4 mg PA + 2 mg LF challenge could limit death to within three days. Then, we evaluated 5E11 efficacy against LT. A prophylactic study showed that the i.v. administration of 40 mg/kg 5E11 four days before lethal dose LT challenge could lead to 100% survival. In therapeutic studies, the i.v. administration of 40 mg/kg 5E11 10 min after lethal dose LT challenge could provide complete protection. Overall, we developed a new LT-challenged rabbit model, and our results indicate that 5E11 shows potential for the clinical application in anthrax treatment.
References
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Jun 25, 2003·Antimicrobial Agents and Chemotherapy·Lance B PricePaul Keim
Jun 19, 2004·The Journal of Antimicrobial Chemotherapy·A AthamnaE Rubinstein
Dec 24, 2004·The EMBO Journal·Melissa DrysdaleTheresa M Koehler
Jan 24, 2006·Infection and Immunity·Johnny W PetersonJagadish Sircar
May 13, 2006·Molecular Microbiology·Thomas Candela, Agnès Fouet
Jun 30, 2009·Molecular Aspects of Medicine·Jean-Nicolas TournierCosima T Baldari
Jul 10, 2009·The New England Journal of Medicine·Thi-Sau MigoneSally D Bolmer
Jul 30, 2009·Molecular Aspects of Medicine·Mahtab Moayeri, Stephen H Leppla
Oct 6, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hui FangDavid M Frucht
Oct 27, 2010·Infection and Immunity·Shu OkugawaStephen H Leppla
Jan 26, 2011·Antimicrobial Agents and Chemotherapy·Shay WeissZeev Altboum
Nov 10, 2011·Toxins·Tao XieDavid M Frucht
Nov 10, 2011·Toxins·Zhaochun ChenRobert Purcell
Apr 25, 2012·Intensive Care Medicine·Caitlin W HicksPeter Q Eichacker
Jul 28, 2012·Clinical and Vaccine Immunology : CVI·Jason E ComerGabriel T Meister
Jan 25, 2013·Toxins·Alfred CoreyGabriel Meister
Mar 6, 2013·Protein Expression and Purification·Ju LiuWei Chen
May 10, 2013·Clinical and Vaccine Immunology : CVI·Boris IoninMario H Skiadopoulos
Aug 28, 2013·Antimicrobial Agents and Chemotherapy·Nutan MytleMario H Skiadopoulos
Apr 16, 2014·Antimicrobial Agents and Chemotherapy·Nina V MalkevichMario H Skiadopoulos
Jan 8, 2015·The Journal of Biological Chemistry·Mahtab MoayeriCharles B Shoemaker
Jul 22, 2015·Annual Review of Microbiology·Mahtab MoayeriShihui Liu
Dec 23, 2015·Health Security·Eileen HuangDana Meaney-Delman
Jul 20, 2016·Antimicrobial Agents and Chemotherapy·Brent J YamamotoNatalya V Serbina
Jul 20, 2016·Antimicrobial Agents and Chemotherapy·Brent J YamamotoNatalya V Serbina
Nov 5, 2016·BMC Infectious Diseases·Breanne M HeadAdrienne F A Meyers
Dec 5, 2017·PloS One·Wanying XuPeter Q Eichacker